surmount-1 tirzepatide weight loss results Body composition changes during reduction with in the SURMOUNT‐1 study of adults with obesity or overweight - Look - 2025 - Diabetes, Obesity and Metabolism Tirzepatide weight-loss study shows promising

Quick Answer: Weight loss may stall on Zepbound due to metabolic adaptation, insufficient time on therapeutic doses, underlying medical conditions, medication interactions, or lifestyle factors that counteract the medication's appetite-suppressing effects

It happens because tirzepatide slows down how quickly your stomach empties, which can leave you feeling queasy especially if you eat too much or too quickly

Eating quickly can have a similar effect, as it gives the stomach less time to signal fullness

Insulin may need temporary dose increases during weeks 3 to 6 to cover the gap period, then reduction as semaglutide reaches full effect

Every participant moves to the next dose at the scheduled four-week mark regardless of side effect severity, unless they meet predefined withdrawal criteria

A few tiny bubbles are cosmetically annoying but not dangerous for subcutaneous injections